Mesoblast Ltd
Mesoblast Limited is an Australia-based biotechnology company.
The business
Mesoblast Limited is an Australia-based biotechnology company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company's Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: Chronic heart failure (CHF) and Chronic low back pain (CLBP) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
Small Caps Research
No research on Mesoblast Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise MSB based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Mesoblast’s Ryoncil becomes first cell therapy approved in the US for acute graft-versus-host disease
Regenerative medicine company Mesoblast (ASX: MSB) has been granted US Food and Drug Administration (FDA) approval for its Ryoncil therapy to treat children with steroid-refractory acute graft-versus-host disease (SR-aGvHD). The off-the-shelf drug derived from bone marrow has become the first mesenchymal stromal cell therapy on the US market to treat the condition, which can occur […]
Mesoblast receives coveted FDA designation for Revascor heart treatment
Cellular medicines developer Mesoblast (ASX: MSB) is celebrating the granting of new US Food and Drug Administration (FDA) approval for its Revascor heart disease treatment. The FDA has granted its highly-sought rare pediatric disease (RPD) designation for Revascor following submission of results from a randomised, controlled trial in children with hypoplastic left heart syndrome (HLHS). […]
TPG Global bids for InvoCare, Xero culls workforce and Myer posts record half sales
Private equity firm TPG Global has taken advantage of beleaguered funeral services company InvoCare’s (ASX: IVC) lacklustre FY2022 results, with a non-binding cash takeover offer valuing it at $12.64 per share. Under the non-binding indicative offer, which was made on Tuesday, TPG is proposing to give InvoCare shareholders $12.65 cash for each share held. This […]
Can these fallen small cap angels regain their wings?
One of the trickiest aspects of investing is deciding whether a fallen angel will ever fly again. If they do regain their wings, the rewards of buying in at distressed levels can be enormous. But as they impress on newcomers in Masterchef safety briefings, trying to catch a falling knife can be highly injurious. As […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.